Prescribed use of anti-anxiety drugs, hypnotics and sedatives, or antidepressants was tied to a higher future risk of ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Corcept Therapeutics (NASDAQ:CORT) said on Thursday that the mid-stage study of its cortisol modulator, dazucorilant, in ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Richter died on Monday, June 2, after a brief illness, according to an email from Clark President David Fithian to the campus community. A celebration of her life and legacy will be celebrated at a ...

Opponents, including some lawmakers, physician groups and the New York State Catholic Conference have cited numerous concerns ...

Despite its growing role in tracking MS activity, serum neurofilament light chain lacks diagnostic specificity, experts say.

Brainstorm tapped Minaris to manufacture NurOwn for its upcoming Phase 3b clinical trial testing the treatment for ALS.

Experts predict cases will rise by 2030, affecting hundreds of Michigan families battling the fatal condition.

Amyotrophic lateral sclerosis (ALS) is a progressive disease that causes severe weakness due to progressive degeneration of a specific set of motor nerves in the spinal cord. People with ALS will ...